{
  "docId": "019de073-a45e-764e-97a1-b4793295a3f1",
  "docSlug": "90578b12d3108983c23425e7ddd95d83",
  "documentTitle": "ATAI | Investor Presentation Deck | 41 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 41,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a third-party study (Yang et al., 2015) to support the claim of a superior therapeutic index for R-ketamine.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a45e-764e-97a1-b4793295a3f1/13",
  "deckHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1",
  "deckJsonHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1.json",
  "deckAnchorHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.15,
        "x": 0.8,
        "y": 0.29
      },
      "kind": "callout",
      "text": "S-Ketamine: greater abuse potential",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "612418f6-bc89-4b48-aed0-c0247b840f29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.15,
        "x": 0.33,
        "y": 0.29
      },
      "kind": "callout",
      "text": "R-Ketamine: lower abuse potential",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c86ded53-01fa-4b14-8bc5-2958d891903b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.08,
        "y": 0.35
      },
      "kind": "chart",
      "text": "CPP scores for R-Ketamine",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ae8d0f5-5d18-4e62-8c47-68f728178bc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "chart",
      "text": "CPP scores for S-Ketamine",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfaebcbf-01c0-4e48-a30e-b5112f0f3be8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Conditioned place preference (CPP) score test (third party study)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "469347d4-e6d3-46f0-bec9-eab4ea49e3bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. Yang et al., \"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects\" (2015).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73311ab6-8356-46dd-ac3f-ca5d6a50a626",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "R-ketamine vs. S-ketamine in preclinical models: Reduced abuse liability potential at effective doses suggest a superior therapeutic index of R-ketamine",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe4efe94-9086-407a-8cd8-044d1d5a9dfb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "3cc34158-e404-4698-8e95-0b03bf8b12a5",
      "evidence": "The slide presents a comparison table with two entries, R-ketamine and S-ketamine, which implies a 2x2 matrix structure.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "967974fb-043f-4700-8349-2c271761b19c",
      "evidence": "Direct side-by-side comparison of two substances across identical metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 41,
      "from": 6,
      "beatId": "54d980bb-d331-41ca-8841-b0eb7beb049c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation provides a solution by showcasing ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 40,
      "from": 10,
      "beatId": "4c06d6d1-b3e1-4c1e-bceb-806b8f57a880",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The presentation provides evidence and proof of the effectiveness of ATAI Life Sciences' treatments through various studies and data.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5cd92045-52c0-4b53-b15d-4dd6b345ff72",
      "evidence": "The presentation showcases ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 1,
      "objective": "How can we effectively treat mental health disorders?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}